Immunocore strategic update: KIMMTRAK expansion, PRAME Phase 3 start, new autoimmune candidates

Immunocore Holdings plc

Preliminary cash and cash equivalents ~$443M as of Dec 31, 2023.
KIMMTRAK expansion: TEBE-AM (2L+ cutaneous melanoma) Phase 2 data Q4 2024; ATOM (adjuvant uveal melanoma) Phase 3 start 2H 2024.
PRAME franchise: PRISM-MEL-301 Phase 3 in 1L cutaneous melanoma to begin randomization Q1 2024; Phase 1/2 data across melanoma, ovarian, NSCLC expected in 2024.
New candidates: IMC-R117C (PIWIL1) for GI cancers; two autoimmune candidates for type 1 diabetes and dermatology.
HIV candidate IMC-M113V Phase 1 MAD data expected 2H 2024; HBV trial amended to include HCC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.